Mutations affecting response and outcomes of patients with CLL. Chlorambucil-based therapy includes chlorambucil, chlorambucil and rituximab, chlorambucil and obinutuzumab; lenalidomide-based therapy includes lenalidomide and lenalidomide and rituximab. FCR, FC plus rituximab.